Proof of Zocor's efficacy in reducing cardiovascular disease was only presented five years after its original introduction, and then only for secondary prevention.
The company countered that rosuvastatin had been tested on larger groups of patients than any other drug in the class, and that its effects should be comparable to the other statins.
In breast cancer, Bevacizumab (Avastin) initially gained approval from the Food and Drug Administration, but subsequently had its license revoked.
[15] In hepatitis C medicine, the surrogate endpoint "Sustained Virological Response" has been used for the approval of expensive drugs known as Direct Acting Antivirals.
More specifically, this study demonstrated that plasma p-tau181 could potentially be used to monitor large-scale population interventions targeting preclinical AD individuals.
[21][22] Reporting surrogate endpoints in randomized controlled trials is an emerging source of concern for clinicians and epidemiologists.